[시장보고서]임상 의사결정 지원 시스템 시장 : 구성요소, 제품, 모델, 제공 모드, 자문 모드, 설정, 유형, 용도, 지역별 예측(-2032년)

임상 의사결정 지원 시스템 시장 : 구성요소, 제품, 모델, 제공 모드, 자문 모드, 설정, 유형, 용도, 지역별 예측(-2032년)

Global Clinical Decision Support System Market Research Report Information by Component By Product, By Model, By Delivery Mode, By Mode of Advice, By Setting By Type, By Application, By Region - Forecast till 2032

상품코드 : 1591333 해당 상품은 즉시 배송 가능합니다

리서치사 : Market Research Future

발행일 : 2024년 10월

페이지 정보 : 영문 184 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,950

￦ 7,344,000

PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다.

US $ 5,950

￦ 8,828,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 기업 내 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다.

US $ 7,250

￦ 10,756,000

PDF & Excel (Enterprise License)

PDF, Excel 보고서를 동일 기업이 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능하며, 인쇄 가능합니다.

한글목차

샘플 요청 목록에 추가

임상 의사결정 지원 시스템 시장 규모는 예측 기간 동안 10.54%의 연평균 복합 성장률(CAGR)로 2024년 36억 7,000만 달러에서 2032년 89억 2,000만 달러 규모로 성장할 것으로 예상됩니다. 이 시장은 노인 인구 증가, 유리한 정부 규제, 데이터 기반 기술에 대한 수요 증가로 인해 성장하고 있습니다.

노년층은 만성질환에 걸리기 쉬워 잦은 진료와 개입이 필요합니다. 그 결과, 노인 인구 증가로 인해 의료기관의 부담이 가중되고 있습니다. 이에 따라 효율적인 의료 서비스 제공을 보장하는 CDSS와 같은 기술에 대한 수요가 증가하고 있습니다. 예를 들어, UN은 2050년까지 전 세계 인구 6명 중 1명이 65세 이상이 될 것으로 예상하고 있으며, 이는 2019년 11명 중 1명에서 크게 증가한 수치이며, Rural Health Information Hub에 따르면 미국에서는 2050년까지 65세 이상 노인이 9,000만 명에 육박할 것으로 예상하고 있습니다. 증가할 것으로 예측되고 있습니다. 또한 2030년에는 미국인 5명 중 1명이 65세 이상이 될 것으로 예상됩니다.

지역별 전망

북미 임상 의사결정 지원 시스템 시장은 2023년 가장 큰 시장 점유율을 차지했습니다. 이는 북미에서 암, 심혈관 질환, 당뇨병, 비만, 관절염과 같은 만성 질환의 발병률이 증가하고 있기 때문입니다. 유럽은 고급 치료 시설에 대한 접근성 덕분에 임상 의사결정 지원 시스템 시장이 두 번째로 높은 시장 점유율을 차지하고 있습니다. 아시아태평양은 환자 인구 증가, 의료 인프라 개선, 암, 정형외과 질환, 심혈관계 질환 등 만성질환 증가로 인해 큰 폭의 성장이 예상됩니다.

세계 임상 의사결정 지원 시스템(Clinical Decision Support System) 시장을 조사했으며, 시장 정의와 개요, 시장 성장에 영향을 미치는 각종 영향요인 분석, 시장 규모 추이 및 예측, 각 부문별/지역별/주요 국가별 분석, 경쟁 환경, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.

영문목차

Global Clinical Decision Support System Market Research Report Information by Component (Software, Services, and Hardware) By Product (Integrated CDSS and Standalone CDSS), By Model (Knowledge-Based CDSS and Non-Knowledge-Based CDSS), By Delivery Mode (On-Premise CDSS and Cloud-Based CDSS), By Mode of Advice (Active CDSS and Passive CDSS), By Setting (Inpatient Settings and Ambulatory Care Settings) By Type (Therapeutic Clinical Decision Support Systems and Diagnostic Clinical Decision Support Systems ), By Application (Advanced Clinical Decision Support Systems and Conventional Clinical Decision Support Systems), By Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

Market Overview

The clinical decision support system market industry is anticipated to experience a compound annual growth rate (CAGR) of 10.54% during the forecast period, increasing from USD 3.67 billion in 2024 to USD 8.92 billion by 2032. The market is experiencing growth due to the increasing geriatric population, favorable government regulations, and the increasing demand for data-driven technologies.

The geriatric population is more susceptible to chronic diseases and necessitates frequent medical examinations and interventions. Consequently, the burden on healthcare institutions is exacerbated by the growing geriatric population. This drives the demand for technologies like CDSS to ensure the provision of efficient care. For instance, the United Nations predicts that by 2050, one in six individuals worldwide will be over the age of 65, a significant increase from one in eleven in 2019. The number of senior adults aged 65 and older is anticipated to increase to nearly 90 million in the United States by 2050, as per the Rural Health Information Hub. In addition, it is anticipated that by 2030, one in five Americans will be 65 years of age or older.

Market segment insights

Software, services, and hardware comprise the Clinical Decision Support System Market segmentation, which is based on component.

The market segmentation is determined by the products, which include Standalone CDSS and Integrated CDSS.

The market segmentation is predicated on a model that encompasses both knowledge-based and non-knowledge-based CDSS.

The Clinical Decision Support System Market segmentation is determined by the delivery mode, which encompasses On-Premises CDSS and Cloud-Based CDSS.

The market segmentation is determined by the mode of advice, which encompasses Active CDSS and Passive CDSS.

On the basis of setting, the market segmentation encompasses both inpatient and ambulatory care contexts.

Therapeutic clinical decision support systems and diagnostic clinical decision support systems comprise the Clinical Decision Support System Market segmentation.

The market segmentation is determined by the application, which encompasses both conventional and advanced clinical decision support systems.

Regional Perspectives

In 2023, the clinical decision support system market in North America held the greatest market share. This is a result of the rising incidence of chronic diseases in the North American region, including cancer, cardiovascular disorders, diabetes, obesity, and arthritis.

In Europe, the clinical decision support system market is the second highest market share, as a result of the region's access to advanced treatment facilities.

The Asia-Pacific clinical decision support system market is anticipated to experience substantial growth as a result of the growing patient population in the region, as well as the improvement of healthcare infrastructure and the prevalence of chronic diseases such as cancer, orthopedic, and cardiovascular diseases.

Major Players

Siemens (Germany), Veradigm LLC (Allscripts Healthcare Solutions Inc) (US), Oracle Corporation (US), IBM (US), Carestream Health (US), Wolters Kluwer N.V. (Netherlands), Epic Systems Corporation (US), Chang Healthcare (US), Medical Information Technology, Inc. (US), and Computer Programs and Systems, Inc (US) are among the key companies in the Clinical Decision Support System Market.

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
- 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TECHNIQUE
3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 RISING GERIATRIC POPULATION
- 4.2.2 FAVORABLE GOVERNMENT REGULATIONS
- 4.2.3 GROWING DEMAND FOR DATA-DRIVEN TECHNOLOGIES
4.3 RESTRAINT
- 4.3.1 RISK OF DATA PRIVACY
- 4.3.2 HIGH COST OF IMPLEMENTATION
4.4 OPPORTUNITIES
- 4.4.1 ADVANCEMENTS IN THE HEALTHCARE IT SECTOR

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS
- 5.1.1 INPUTS
- 5.1.2 DESIGN & DEVELOPMENT
- 5.1.3 OUTPUT
- 5.1.4 SALES & DISTRIBUTION
- 5.1.5 POST-SALES SERVICES
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 BARGAINING POWER OF SUPPLIERS
- 5.2.2 BARGAINING POWER OF BUYERS
- 5.2.3 THREAT OF NEW ENTRANTS
- 5.2.4 THREAT OF SUBSTITUTES
- 5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL CLINICAL DECISION SUPPORT SYSTEM MARKET
- 5.3.1 OVERVIEW
- 5.3.2 IMPACT ON SUPPLY CHAIN
- 5.3.3 IMPACT ON DEVELOPMENT
- 5.3.4 IMPACT ON REGIONS
- 5.3.5 MANAGING POST-COVID CARE THROUGH CLINICAL DECISION SUPPORT SYSTEMS

6 GLOBAL CLINICAL DECISION SUPPORT SYSTEM MARKET, BY PRODUCT

6.1 OVERVIEW
6.2 SOFTWARE
6.3 SERVICES
6.4 HARDWARE

7 GLOBAL CLINICAL DECISION SUPPORT SYSTEM MARKET, BY PRODUCT

7.1 OVERVIEW
7.2 INTEGRATED CDSS
7.3 STANDALONE CDSS

8 GLOBAL CLINICAL DECISION SUPPORT SYSTEM MARKET, BY MODEL

8.1 OVERVIEW
8.2 KNOWLEDGE-BASED CDSS
8.3 NON-KNOWLEDGE-BASED CDSS

9 GLOBAL CLINICAL DECISION SUPPORT SYSTEM MARKET, BY DELIVERY MODE

9.1 OVERVIEW
9.2 ON-PREMISE CDSS
9.3 CLOUD-BASED CDSS

10 GLOBAL CLINICAL DECISION SUPPORT SYSTEM MARKET, BY MODE OF ADVICE

10.1 OVERVIEW
10.2 ACTIVE CDSS
10.3 PASSIVE CDSS

11 GLOBAL CLINICAL DECISION SUPPORT SYSTEM MARKET, BY SETTING

11.1 OVERVIEW
11.2 INPATIENT SETTINGS
11.3 AMBULATORY CARE SETTINGS

12 GLOBAL CLINICAL DECISION SUPPORT SYSTEM MARKET, BY TYPE

12.1 OVERVIEW
12.2 THERAPEUTIC CDSS
12.3 DIAGNOSTIC CDSS

13 GLOBAL CLINICAL DECISION SUPPORT SYSTEM MARKET, BY APPLICATION

13.1 OVERVIEW
13.2 ADVANCED CDSS
13.3 CONVENTIONAL CDSS

14 GLOBAL CLINICAL DECISION SUPPORT SYSTEM MARKET, BY REGION

14.1 OVERVIEW
14.2 NORTH AMERICA
- 14.2.1 US
- 14.2.2 CANADA
14.3 EUROPE
- 14.3.1 GERMANY
- 14.3.2 FRANCE
- 14.3.3 UK
- 14.3.4 ITALY
- 14.3.5 SPAIN
- 14.3.6 REST OF EUROPE
14.4 ASIA-PACIFIC
- 14.4.1 CHINA
- 14.4.2 JAPAN
- 14.4.3 INDIA
- 14.4.4 AUSTRALIA
- 14.4.5 SOUTH KOREA
- 14.4.6 REST OF ASIA-PACIFIC
14.5 REST OF THE WORLD
- 14.5.1 MIDDLE EAST & AFRICA
- 14.5.2 LATIN AMERICA

15 COMPETITIVE LANDSCAPE

15.1 INTRODUCTION
15.2 MARKET SHARE ANALYSIS,
15.3 COMPETITOR DASHBOARD
15.4 PUBLIC PLAYERS STOCK SUMMARY
15.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
15.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 15.6.1 /PRODUCT/SOLUTION/SERVICE LAUNCHAPPROVAL
- 15.6.2 COLLABORATION
- 15.6.3 ACQUISITION
- 15.6.4 PARTNERSHIP

16 COMPANY PROFILES

16.1 SIEMENS
- 16.1.1 COMPANY OVERVIEW
- 16.1.2 FINANCIAL OVERVIEW
- 16.1.3 PRODUCTS OFFERED
- 16.1.4 KEY DEVELOPMENTS
- 16.1.5 SWOT ANALYSIS
- 16.1.6 KEY STRATEGIES
16.2 VERADIGM LLC (ALLSCRIPTS HEALTHCARE SOLUTIONS INC)
- 16.2.1 COMPANY OVERVIEW
- 16.2.2 FINANCIAL OVERVIEW
- 16.2.3 PRODUCTS OFFERED
- 16.2.4 KEY DEVELOPMENTS
- 16.2.5 SWOT ANALYSIS
- 16.2.6 KEY STRATEGIES
16.3 ORACLE CORPORATION
- 16.3.1 COMPANY OVERVIEW
- 16.3.2 FINANCIAL OVERVIEW
- 16.3.3 PRODUCTS OFFERED
- 16.3.4 KEY DEVELOPMENTS
- 16.3.5 KEY STRATEGIES
16.4 IBM
- 16.4.1 COMPANY OVERVIEW
- 16.4.2 FINANCIAL OVERVIEW
- 16.4.3 SOLUTION OFFERED
- 16.4.4 KEY DEVELOPMENTS
- 16.4.5 SWOT ANALYSIS
- 16.4.6 KEY STRATEGIES
16.5 CARESTREAM HEALTH
- 16.5.1 COMPANY OVERVIEW
- 16.5.2 FINANCIAL OVERVIEW
- 16.5.3 SERVICE/SOLUTION OFFERED
- 16.5.4 KEY DEVELOPMENTS
- 16.5.5 KEY STRATEGIES
16.6 WOLTERS KLUWER N.V.
- 16.6.1 COMPANY OVERVIEW
- 16.6.2 FINANCIAL OVERVIEW
- 16.6.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
- 16.6.4 KEY DEVELOPMENTS
- 16.6.5 SWOT ANALYSIS
- 16.6.6 KEY STRATEGIES
16.7 EPIC SYSTEMS CORPORATION
- 16.7.1 COMPANY OVERVIEW
- 16.7.2 FINANCIAL OVERVIEW
- 16.7.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
- 16.7.4 KEY DEVELOPMENTS
- 16.7.5 SWOT ANALYSIS
- 16.7.6 KEY STRATEGIES
16.8 CHANG HEALTHCARE
- 16.8.1 COMPANY OVERVIEW
- 16.8.2 FINANCIAL OVERVIEW
- 16.8.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
- 16.8.4 KEY DEVELOPMENTS
- 16.8.5 KEY STRATEGIES
16.9 MEDICAL INFORMATION TECHNOLOGY, INC.
- 16.9.1 COMPANY OVERVIEW
- 16.9.2 FINANCIAL OVERVIEW
- 16.9.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
- 16.9.4 KEY DEVELOPMENTS
- 16.9.5 KEY STRATEGIES
16.10 COMPUTER PROGRAMS AND SYSTEMS, INC.
- 16.10.1 COMPANY OVERVIEW
- 16.10.2 FINANCIAL OVERVIEW
- 16.10.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
- 16.10.4 KEY DEVELOPMENTS
- 16.10.5 KEY STRATEGIES

한글목차

목차

제1장 주요 요약

제2장 시장 개요

제3장 조사 방법

제4장 시장 역학

제5장 시장 요인 분석

제6장 세계의 임상 의사결정 지원 시스템 시장 : 컴포넌트별

제7장 세계의 임상 의사결정 지원 시스템 시장 : 제품별

제8장 세계의 임상 의사결정 지원 시스템 시장 : 모델별

제9장 세계의 임상 의사결정 지원 시스템 시장 : 딜리버리 모드별

제10장 세계의 임상 의사결정 지원 시스템 시장 : 조언 모드별

제11장 세계의 임상 의사결정 지원 시스템 시장 : 설정별

제12장 세계의 임상 의사결정 지원 시스템 시장 : 유형별

제13장 세계의 임상 의사결정 지원 시스템 시장 : 용도별

제14장 세계의 임상 의사결정 지원 시스템 시장 : 지역별

제15장 경쟁 구도

제16장 기업 개요

제17장 데이터 인용